Table 1_A novel α-conotoxin [D1G, ΔQ14] LvIC decreased mouse locomotor activity.xls by Wen Wang (6570)

The early endosomal membranes are enriched with PE in yeast and plant cells. by Kai Xu (122914)

Comparison of current amplitudes from mutant and WT mBest2 Cl⁻ channels. by Agata Kranjc (253149)

“…E306A had a mean value not significantly different from WT (P = 0.5; N = 7–8). …”

Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner by Khondoker Alam (1443499)

“…Pretreatment with bortezomib (50–250 nM, 2–7 h) significantly decreased transport of [³H]CCK-8, a specific OATP1B3 substrate, in HEK293-OATP1B3 and human sandwich-cultured hepatocytes (SCH). …”

Effect of OKN-007 on diffusion measured as ADC values in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)

Effect of OKN-007 on perfusion rates measured as rCBF in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)

File S1 - S-Nitrosoglutathione Accelerates Recovery from 5-Fluorouracil-Induced Oral Mucositis by Maria Adriana Skeff (670466)

Bcl-xL protein levels were decreased in response to siRNA transfection in A549, SK-LU1 and NP-69 cells. by Norahayu Othman (495150)

“…<p>(<b>A</b>) Western blot indicating a significant decrease in Bcl-xL protein levels in comparison to non-transfected cells 48 h post-transfection. …”

Morphometric data of layer II/III and V/VI pyramidal neurons. by Janine R. Neumann (6330863)

Effect of OKN-007 on the immunoexpression of SULF2 in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)

“…OKN-007 (NR); (4) Normal vs. OKN-007 (R); (5) UT vs. OKN-007 (NR); and (6) Normal vs. OKN-007 (NR).…”

Effect of OKN-007 on the immunoexpression of PDGFR-α in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)

“…OKN-007 (NR); (4) Normal vs. OKN-007 (R); (5) UT vs. OKN-007 (NR); and (6) Normal vs. OKN-007 (NR).…”

Western-blot and BN-PAGE analyses of brain mitochondria from WT and AOX mice. by Riyad El-Khoury (104865)

“…<p>A, Western-blot analyses of the steady state of different RC complexes (CI, NDUFA12; CII, SDHA; CIII, Core1; CIV, Cox1 and, CV, ß-ATPase) of mitochondria extracted from 11 organs from four WT and four AOX mice. B, RC complexes (I, III, IV and V) from three different organs, highly (brain), mildly (heart) and weakly (liver) expressing the AOX, were quantified as a ratio to complex II with no significant difference being observed between WT and AOX mice. …”

An example of regional-level GIS outputs derived via the questionnaire data: Collated fisher responses to trends in dugong captures in fishing gear across all recorded years, scale... by Nicolas J. Pilcher (203564)

Percent live fetuses after LPS90 and LPS250 compared with Wt controls. by Maide Ozen (6551636)

“…<p>Intraperitoneal administration of LPS at a dose of 250 μg/kg at E16.5 resulted in a significant decrease in the percentage of live fetuses compared with GA-matched Wt controls. …”

FTY720 potentiated the activity of cisplatin. by Laura L. Stafman (6577184)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”